FOLD — Amicus Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.55bn
- $4.65bn
- $634.21m
Amicus Therapeutics' Q2 revenue up more than expected on Galafold demand
Brief: Amicus Therapeutics Announces Approval Of Pombiliti®
Brief: Amicus Therapeutics Q1 Revenue USD 125.2 Million Vs. IBES Estimate USD 135.9 Million
Brief: Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States
U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp
Brief: Amicus Therapeutics Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Amicus Therapeutics Q4 Net Income USD 14.7 Million
Brief: Amicus Therapeutics Announces Q3 2024 Financial Results And Corporate Updates
Brief: Amicus Therapeutics Q3 Revenue USD 141.5 Million Vs. IBES Estimate USD 135.3 Million
Brief: Amicus Therapeutics Enters License Agreement With Teva Pharmaceuticals
Jefferies initiates Amicus Therapeutics with 'buy'
U.S. RESEARCH ROUNDUP- Broadcom, Costco Wholesale, Saia
U.S. RESEARCH ROUNDUP- Advance Auto Parts, Molina Healthcare, Walmart
Amicus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Amicus Therapeutics Q2 Revenue USD 126.7 Million Vs. IBES Estimate USD 121.2 Million
Amicus Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Deere & Co, Under Armour, Walmart
U.S. RESEARCH ROUNDUP- Corpay, Epam Systems, MKS Instruments
Amicus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary